Lianlian Li

Title: Lianlian Li: Innovator in Cancer Treatment

Introduction

Lianlian Li is a notable inventor based in Jinan, China. He has made significant contributions to the field of medicine, particularly in the treatment of non-small cell lung carcinoma. His innovative approach has led to the development of a unique strain that shows promise in cancer therapy.

Latest Patents

Lianlian Li holds a patent for the "Application of Derivatives of Clostridium Ghonii," specifically focusing on the application of derivatives of MW-DCG-HNCv-18 in the preparation of medicines for treating non-small cell lung carcinoma. This invention discloses a medicine that combines the derivatives of MW-DCG-HNCv-18 strain with Docetaxel as the active ingredients. The MW-DCG-HNCv-18 strain has been found to have a specific inhibition effect on non-small cell lung carcinoma for the first time. The inhibition effect is significantly superior to that of other known similar strains. Through screening, it has been determined that the MW-DCG-HNCv-18 strain exhibits a more prominent inhibition effect on non-small cell lung carcinoma when combined with Docetaxel injection.

Career Highlights

Lianlian Li has worked with Shandong Xinchuang Biotechnology Co., Ltd. and Shandong Xinchuang Biological Technology Co., Ltd. His work in these companies has been instrumental in advancing biotechnological applications in medicine.

Collaborations

Some of his notable coworkers include Laitian Xing and Yong Wang. Their collaboration has contributed to the innovative research and development in the field of cancer treatment.

Conclusion

Lianlian Li's contributions to the field of medicine, particularly in cancer treatment, highlight the importance of innovation in healthcare. His patented work demonstrates the potential of new strains in providing effective therapies for challenging diseases.